Subscribe To
Biogen shares rise on imminent approval of alzheimer's drug following fda panel vote
Biogen Inc (NASDAQ:BIIB) shares rose in pre-market trading on Monday after a Food and Drug Administration (FDA) panel voted in favor of Eisai and Biog...
June 12, 2023, 8:46 am
5 things to know before markets open
UBS completes its takeover of Credit Suisse and Biogen wins key FDA support for its alzheimer's disease...
June 12, 2023, 7:35 am
Biogen rises as fda panel backs alzheimer's drug, easing safety concerns
Shares of Biogen Inc rose 4% in premarket trade on Monday as an unanimous backing of the company's alzheimer...
June 12, 2023, 6:26 am
Biogen stock climbs on drug approval recommendation, oracle shares rise ahead of earnings, and other stocks on the move
Biogen Inc. shares BIIB, +1.31% rallied 5% following a full-day halt during the regular session as a Food and Drug Administration committee convened t...
June 12, 2023, 5:38 am
Biogen inches closer to fda approval for its alzheimer's drug
Shares of Biogen Inc (NASDAQ: BIIB) gained nearly 10% in extended hours after the biotech firm edged closer to winning FDA approval for its ...
June 10, 2023, 2:33 pm
: biogen stock rallies after full-day halt as fda panel recommends alzheimer’s drug for approval
Biogen Inc. BIIB shares rallied in the extended session late Friday following a full-day halt after the biotech company received a recommendation from...
June 9, 2023, 11:27 pm
Fda advisory committee votes unanimously to confirm the clinical benefit of leqembi® (lecanemab-irmb) for the treatment of alzheimer’s disease
Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory Phase 3 Clarity AD clinical trial in...
June 9, 2023, 10:45 pm
Biogen stock rallies after full-day halt as fda panel recommends alzheimer's drug for approval
Biogen Inc. BIIB, +1.31% shares rallied in the extended session late Friday following a full-day halt after the biotech company received a recommendat...
June 9, 2023, 7:27 pm
Here's what the fda's endorsement of the alzheimer's drug leqembi means for biogen
Matt Herper, Stat News senior writer, joins 'Closing Bell: Overtime' to discuss the FDA advisers' unanimous vote to recommend Biogen ...
June 9, 2023, 5:33 pm
Biogen stock halted as it faces make-or-break moment for alzheimer's treatment
Biogen stock was halted Friday as a panel of experts to the FDA debated the merits of its alzheimer's t...
June 9, 2023, 2:29 pm
Fda advisors to weigh whether alzheimer's drug leqembi should receive full approval
Medicare has promised to broadly cover Leqembi, which costs $26,500 per year, if the FDA grants full approval of the treatment....
June 9, 2023, 10:07 am
Fda panel to debate us approval for alzheimer's drug from eisai and biogen
A panel of experts on Friday will discuss whether to recommend traditional U.S. regulatory approval for Eisai and Biogen's new ...
June 9, 2023, 7:04 am
Biogen (biib), eisai's alzheimer drug likely to get full fda nod
Based on briefing documents issued by the FDA, a full regulatory approval is expected on Biogen (BIIB)/Eisai's ...
June 8, 2023, 1:53 pm
Johnson & johnson relinquishes top spot to eli lilly, shares undervalued amid technical risks
Eli Lilly has surpassed Johnson & Johnson in market cap for the first time, driven by LLY's breakthroughs in obesity and ...
June 8, 2023, 1:23 pm
Dow jones newswires: eisai shares rise as fda memo raises hopes for full approval of alzheimer’s drug
Eisai shares rose sharply Thursday morning after the U.S. Food and Drug Administration’s review memo on Leqembi raised expectations for full approva...
June 8, 2023, 2:00 am
Eisai shares rise as fda memo raises hopes for full approval of alzheimer's drug
Eisai shares 4523, +8.98% rose sharply Thursday morning after the U.S. Food and Drug Administration's review memo on Leqembi raised expectations for f...
June 7, 2023, 10:00 pm
Why shares of newamsterdam pharma were plummeting on wednesday
NewAmsterdam is a clinical-stage biopharmaceutical company with a lead therapy candidate that lowers cholesterol levels. The company is examining the ...
June 7, 2023, 3:55 pm
Fda staff say eisai's alzheimer's drug may get full approval despite concerns
Staff reviewers of the U.S. Food and Drug Administration (FDA) said on Wednesday that Eisai and Biogen's alzhe...
June 7, 2023, 11:11 am
Coya therapeutics stock gains on new data from alzheimer's study
Shares of Coya Therapeutics Inc. COYA, +3.33% gained 12% premarket on Wednesday after the clinical-stage biotech company released new data from a stud...
June 7, 2023, 8:40 am
Anavex's blarcamesine: sigma-1 receptor agonists and antioxidants for alzheimer's disease
Blarcamesine, a sigma-1 receptor agonist, may be a more effective antioxidant than Aricept and galantamine in treating ...
June 6, 2023, 9:00 pm